How to Fill Out SEC Form S-1 (w/Examples) + FAQs

Filing SEC Form S-1 is the federal registration statement a company must submit before it sells securities to the public in the United States for the first time. You fill it out by drafting a prospectus that follows Regulation S-K for narrative disclosures and Regulation S-X for audited financial statements, paying the SEC filing fee, and submitting through the EDGAR system.

The Form S-1 is the gateway document for nearly every traditional initial public offering, and a single mistake in its drafting can trigger personal liability for officers, directors, and underwriters under Section 11 of the Securities Act. According to the SEC’s 2024 Agency Financial Report, companies filed more than 600 Form S-1 registration statements during the prior fiscal year, and roughly one in three received substantive staff comments that required at least one amendment before the registration became effective.

Here is what you will learn in this guide:

• 📋 How to complete every Item in Parts I and II of Form S-1, line by line
• ⚖️ Which federal laws, rules, and SEC staff guidance govern each disclosure
• 💰 The real costs, fees, and timeline for an S-1 from kickoff to effectiveness
• 🧾 How real filers like Reddit, Klaviyo, Instacart, and Arm Holdings drafted key sections
• 🚫 The most common mistakes filers make and the consequences of each one

What Form S-1 Is and Why It Exists

Form S-1 is the default registration statement under the Securities Act of 1933, which Congress passed after the 1929 market crash to force companies to give investors full and fair disclosure before selling stock. The form has two parts. Part I is the prospectus that goes to investors. Part II contains additional information that stays on file with the SEC but is still public on EDGAR.

The form exists because Section 5 of the Securities Act makes it illegal to offer or sell a security in interstate commerce unless a registration statement is on file and effective. The plain-English purpose of this rule is to stop companies from raising public money based on hype alone. The consequence of ignoring Section 5 is severe, because buyers can rescind their purchases under Section 12(a)(1) and recover their money plus interest. A common misconception is that a private company can quietly “test the waters” without restrictions, but only emerging growth companies and certain other issuers can use that path under tight conditions.

A real-world example helps. When Reddit filed its S-1 in February 2024, the company had to disclose every material risk, every related-party transaction, and every line of audited financials before a single share could trade on the New York Stock Exchange. Reddit could not advertise the offering broadly until the SEC declared the registration effective, and any “gun-jumping” press release before that point would have violated Section 5 and could have forced a “cooling-off” period that delayed the IPO.

Who Must File Form S-1

Any domestic U.S. issuer that wants to sell securities to the public and does not qualify for a shorter form like Form S-3 must file Form S-1. Form S-3 is reserved for seasoned issuers that have been reporting for at least 12 months and meet a public float test. First-time issuers, recent spin-offs, and companies that have not yet built a reporting history almost always start with Form S-1.

Foreign private issuers use Form F-1 instead, which mirrors much of S-1 but allows International Financial Reporting Standards financials. Smaller issuers raising under \$75 million in any 12-month period sometimes use Regulation A+ and Form 1-A as a lighter alternative. The consequence of picking the wrong form is a likely SEC bounce-back letter that resets your clock by weeks or months.

When You File Form S-1

You file Form S-1 once your underwriters, auditors, and counsel have a clean draft of the prospectus and audited financials that comply with PCAOB standards. Most companies start drafting six to nine months before they want to price the offering. Emerging growth companies under the JOBS Act may submit a confidential draft first, then file publicly at least 15 days before the road show under Section 6(e).

Part I: The Prospectus, Item by Item

Part I of Form S-1 is the prospectus, and its content is dictated mainly by Items 1 through 11A of Regulation S-K. Every item has its own purpose, its own risks, and its own common drafting traps.

Item 1: Forepart of Registration Statement and Outside Front Cover Page of Prospectus

Item 1 controls the cover page, and it is governed by Item 501 of Regulation S-K. The plain-English rule is that the cover must show the issuer’s name, the title and amount of securities, the price, the underwriting discount, and the proceeds to the issuer in a clean tabular format. The consequence of cluttering the cover with marketing language is a near-certain comment letter, because Rule 421(b) bars “extraneous” content on the cover.

A real example is Klaviyo’s 2023 S-1 cover page, which showed exactly the price range, share count, ticker symbol “KVYO,” and the names of the underwriters in a single, scannable block. A common misconception is that the cover can include the company logo or tagline, but the SEC staff consistently asks filers to strip such marketing flourishes.

Item 2: Inside Front and Outside Back Cover Pages of Prospectus

Item 2 covers the inner front and outer back pages, and it requires a “dealer prospectus delivery obligation” legend under Rule 174. The plain-English point is that brokers selling the new stock must keep delivering the prospectus for 25 or 90 days after effectiveness, depending on whether the issuer is already a reporting company. The consequence of skipping this legend is that downstream brokers may unknowingly violate Section 5.

For example, Sarah Chen is a syndicate broker at a midsize bank, and her compliance team relies on the back-cover legend to know exactly when the delivery duty ends. Without that legend, Sarah’s firm could face liability under Section 4(a)(3). A common misconception is that the legend is boilerplate that does not need to be tailored, but the duration must match the issuer’s reporting status precisely.

Item 3: Summary Information, Risk Factors, and Ratio of Earnings to Fixed Charges

Item 3 starts the body of the prospectus with the summary, the risk factors, and any required ratios, and it is governed by Items 503 and 105 of Regulation S-K. The summary must give a brief overview of the company, the offering, and the financial highlights without simply repeating the full prospectus. The consequence of writing a bloated summary is an SEC comment that forces a rewrite and a new printer cycle.

Risk factors must be specific to the issuer, organized under headings, and written in plain English under Rule 421(d). Generic risks like “the stock market is volatile” must be cut, because the SEC’s 2020 Modernization Release requires a tailored, principal-risks approach. A real-world example is Instacart’s 2023 S-1 risk factor section, which led with grocery-specific concentration risk, gig-worker classification risk, and Apple App Store policy risk, all of which had clear consequences for revenue.

Item 4: Use of Proceeds

Item 4 follows Item 504 of Regulation S-K, and it tells investors exactly how the company plans to spend the IPO money. The plain-English rule is that vague language like “general corporate purposes” is allowed only if you have no specific plan. The consequence of being too vague when you do have a plan is a fraud claim under Section 11 if the actual spending diverges sharply.

For example, Marcus Johnson is the CFO of a hypothetical SaaS company called BrightOps, and he plans to use \$60 million of \$200 million for a specific acquisition already under letter of intent. Marcus must disclose that allocation, because Item 504(a)(1) requires it. A common misconception is that you can hide pending M&A under a generic heading, but the SEC staff routinely asks for specificity.

Item 5: Determination of Offering Price

Item 5 follows Item 505 of Regulation S-K, and it forces the issuer to explain how it set the price for an IPO when there is no public trading market. The plain-English rule is that you must list factors like historical earnings, book value, market multiples of comparable public companies, and underwriter input. The consequence of skipping this explanation is that investors may sue under Section 12(a)(2) if the price later collapses and disclosure looked thin.

A real example is Arm Holdings’ 2023 F-1, which carefully described the use of comparable semiconductor multiples to anchor the \$51 IPO price. A common misconception is that underwriter judgment alone is enough, but the staff almost always asks for the underlying inputs.

Item 6: Dilution

Item 6 mirrors Item 506 of Regulation S-K, and it requires a tabular dilution analysis when the offering price is materially higher than the net tangible book value per share. The plain-English point is that new investors are paying more per share than insiders, and the table shows the gap. The consequence of omitting it for a “cheap stock” issuer is a quick comment letter and possible delay.

Item 7: Selling Security Holders

Item 7 follows Item 507 of Regulation S-K and applies when existing shareholders are also selling shares in the offering. The plain-English rule is that you must list each selling holder by name, with the number of shares owned before, the number being sold, and the number owned after. The consequence of leaving out a selling holder is that those shares cannot be sold legally in the offering.

Item 8: Plan of Distribution

Item 8 mirrors Item 508 of Regulation S-K, and it lays out how the securities will be distributed to investors. For a firm-commitment IPO, you must name the underwriters, describe the underwriting discount, and explain stabilization and over-allotment options under Regulation M. A common misconception is that “best efforts” deals do not need detailed plans, but FINRA Rule 5110 still requires careful disclosure of compensation.

Item 9: Description of Securities to Be Registered

Item 9 follows Item 202 of Regulation S-K and tells investors what they are buying. For common stock, you describe voting rights, dividend rights, and liquidation rights. For debt, you describe interest, maturity, covenants, and ranking. The consequence of incomplete description is an investor lawsuit if a hidden feature, like a dual-class voting structure, surprises the market later.

For example, Reddit’s S-1 disclosed a Class A and Class B structure where Class B carried 10 votes per share, and the description had to make the founder control crystal clear.

Item 10: Interests of Named Experts and Counsel

Item 10 follows Item 509 of Regulation S-K and requires disclosure of any material financial interest that auditors, counsel, or other experts have in the issuer. The plain-English rule is that if your auditor owns shares or your law firm took stock as a fee, the public must know. The consequence of nondisclosure is a potential independence violation that could force a re-audit and delay the IPO by months.

Item 11: Information with Respect to the Registrant

Item 11 is the largest single item, and it pulls in dozens of sub-items from Regulation S-K, including business description, properties, legal proceedings, market for registrant’s common equity, selected financial data, MD&A, quantitative and qualitative disclosures about market risk, directors and executive officers, executive compensation, security ownership, related-person transactions, and corporate governance.

The MD&A section, governed by Item 303 of Regulation S-K, is often the most heavily commented part of the filing. The plain-English rule is that you must explain results through the eyes of management, including known trends and uncertainties. The consequence of skipping a known trend, like a major customer going to bankruptcy, is a Caterpillar-style enforcement action under Section 13(a).

Executive compensation under Item 402 requires the Summary Compensation Table for the named executive officers. A common misconception is that private-company option grants do not need fair-value disclosure, but the staff routinely asks about “cheap stock” issued in the 12 months before the IPO. Priya Patel, a CFO at a hypothetical biotech named NeuroPath, learned this the hard way when the staff demanded a contemporaneous valuation report for grants made nine months before filing.

Item 11A: Material Changes

Item 11A applies when the issuer is incorporating by reference and there have been material changes since the last filing. For first-time S-1 filers, this Item is usually marked “Not Applicable.”

Item 12: Incorporation of Certain Information by Reference

Item 12 is generally available only to issuers that meet certain reporting and float thresholds under General Instruction VII. Most first-time IPO issuers cannot use it, but seasoned issuers using S-1 for resale shelves can.

Item 12A: Disclosure of Commission Position on Indemnification for Securities Act Liabilities

Item 12A requires the standard “in the opinion of the Commission, indemnification … is against public policy” legend. The consequence of omitting it is a quick comment letter, because the language is mandatory under Item 510 of Regulation S-K.

Part II: Information Not Required in Prospectus

Part II contains items that the SEC requires but that do not need to be delivered to investors. It still appears on EDGAR for public review.

Item 13: Other Expenses of Issuance and Distribution

Item 13 lists every fee tied to the offering, like SEC registration fees, FINRA fees, listing fees, legal fees, accounting fees, printing fees, and transfer agent fees. The plain-English rule is that the table should add up to a believable total. The consequence of lowballing legal fees is an embarrassing comment letter pointing to industry data.

Item 14: Indemnification of Directors and Officers

Item 14 requires you to summarize the indemnification provisions in your charter, bylaws, and any indemnification agreements, plus relevant state law such as Delaware General Corporation Law Section 145. A common misconception is that you can simply attach the bylaws and stop, but the staff wants a narrative.

Item 15: Recent Sales of Unregistered Securities

Item 15 forces disclosure of every private placement during the past three years, including the buyer category, the price, and the exemption relied on, like Section 4(a)(2) or Rule 506(b). The consequence of missing a sale is a potential failure-to-register claim that can hold up effectiveness.

Item 16: Exhibits and Financial Statement Schedules

Item 16 controls the exhibit index, governed by Item 601 of Regulation S-K. You must file the underwriting agreement, charter, bylaws, specimen stock certificate, material contracts, list of subsidiaries, auditor consent, and legal opinion, among others. The plain-English rule is that exhibits must be filed when you go effective, even if some can be filed by amendment.

Item 17: Undertakings

Item 17 lists standard “undertakings” the issuer agrees to, such as filing a post-effective amendment for any material change. The consequence of omitting required undertakings is a comment letter that delays effectiveness.

Financial Statements: Regulation S-X Requirements

Form S-1 financial statements live inside Item 11 but must comply with Regulation S-X. For most domestic issuers, you need three years of audited income statements, cash flow statements, and statements of stockholders’ equity, plus two years of audited balance sheets. Emerging growth companies can present only two years of audited income statements under Section 7(a)(2)(A) of the Securities Act.

The audit must be done by a PCAOB-registered firm under PCAOB auditing standards. The consequence of using a non-registered firm is that the SEC will not declare the registration effective, period. A real example is when smaller filers occasionally try to use a regional firm not registered with PCAOB and lose months re-auditing.

Interim periods must follow Article 10 of Regulation S-X and the SEC Financial Reporting Manual. The “staleness rules” in Rule 3-12 force you to update financials at set intervals, and missing a staleness date is one of the most common reasons IPOs slip a quarter.

Filing Fees, EDGAR, and Plain English

The SEC filing fee for fiscal year 2026 is set each October by the SEC and is calculated on the maximum aggregate offering price. Recent rates have hovered around \$147 per million dollars of registration. Filers also pay FINRA Public Offering filing fees under FINRA Rule 5110, which has its own per-filing minimum and maximum.

You file through EDGAR, and as of 2025 every filer must use the new EDGAR Next access protocols, which require multifactor authentication and dedicated account roles. The consequence of trying to file without an updated EDGAR Next account is a hard rejection at the door.

The Plain English Handbook and Rule 421 require short sentences, active voice, everyday words, and no legal jargon in the cover page, summary, and risk factors. A common misconception is that lawyers can keep using passive voice, but Item 421(d) makes plain English mandatory in those sections.

Three Common S-1 Scenarios

The next three tables show how typical drafting choices play out in practice.

Scenario 1: Emerging Growth Company Confidential Submission

Drafting Choice	Filing Outcome
EGC submits draft S-1 confidentially under Section 6(e)	SEC staff reviews privately, no public exposure yet
EGC waits until 15 days before road show to file publicly	Filer keeps competitive secrets longer, lowers signaling risk
EGC presents only two years of audited financials	Saves audit fees, satisfies JOBS Act relief
EGC skips Compensation Discussion and Analysis	Cuts disclosure prep, allowed under Item 402(l)

Scenario 2: Vague Use of Proceeds Disclosure

Drafting Choice	Filing Outcome
Issuer says “general corporate purposes” with M&A under LOI	SEC issues comment letter demanding specifics
Issuer refuses to amend	Staff withholds acceleration of effectiveness
Issuer adds named acquisition target and dollar amount	Staff clears the comment, deal moves forward
Issuer later spends money on something else	Possible Section 11 claim if the change is material

Scenario 3: Cheap Stock Option Grants Pre-IPO

Drafting Choice	Filing Outcome
Issuer grants options at \$2 nine months before \$15 IPO	Staff requests contemporaneous 409A valuation support
Issuer cannot produce contemporaneous report	Issuer must record extra stock-based compensation
Issuer restates financial statements	IPO timeline slips by a full quarter
Issuer documents valuation properly upfront	No comment, IPO stays on track

Concrete Named-Person Examples

Daniel Brooks is the general counsel of a hypothetical fintech called LedgerLine, and he is preparing the company’s first S-1. Daniel must coordinate the underwriting agreement, the auditor consent, and the legal opinion as exhibits under Item 601. His goal is to file publicly by July, so his team works backward from the staleness rule to lock the audit window.

Elena Rivera is the CFO of a hypothetical clean energy company called SolaraGrid, and she is choosing between Form S-1 and Regulation A+. Elena’s offering target is \$120 million, which exceeds the Reg A+ ceiling, so she files Form S-1. Her use-of-proceeds table breaks out factory build-out, working capital, and debt repayment in compliance with Item 504.

James Whitaker is an outside securities partner advising a hypothetical biotech named NeuroPath on its IPO. James leads the drafting of the risk factors, focusing on FDA approval risk, clinical trial concentration, and intellectual property risk under Item 105. His firm’s legal opinion is filed as Exhibit 5.1 and confirms the shares will be validly issued, fully paid, and non-assessable.

Mistakes to Avoid

Below are the most common Form S-1 mistakes and the consequence of each.

• Filing without PCAOB-registered audited financials, which guarantees a rejection at effectiveness time.
• Burying related-party transactions outside Item 404, which can trigger an enforcement action and Section 11 liability.
• Using boilerplate “any of these factors could harm us” risk language banned by the SEC Modernization Release.
• Skipping a contemporaneous 409A valuation for pre-IPO option grants, which forces a cheap stock restatement.
• Promoting the offering in press releases before effectiveness, which violates Section 5(c) and creates a gun-jumping issue.
• Failing to update for staleness dates, which delays effectiveness by a full quarter.
• Forgetting the dealer prospectus delivery legend on the back cover, which exposes brokers to Section 4 liability.
• Missing exhibits like the underwriting agreement or legal opinion under Item 601, which prevents acceleration of effectiveness.
• Misclassifying the issuer as a smaller reporting company without meeting the SRC definition, which leads to inadequate disclosure.
• Treating MD&A as a financial summary instead of a forward-looking trends analysis under Item 303.

Do’s and Don’ts of Form S-1 Drafting

These quick rules keep your filing on track.

• Do tailor each risk factor to your specific business, because Item 105 demands principal, not generic, risks.
• Do use the Plain English Handbook for every cover, summary, and risk factor section to avoid Rule 421 comments.
• Do plan for a confidential submission if you qualify, because it lets you fix problems privately.
• Do refresh financials before each staleness deadline to keep effectiveness on schedule.
• Do prepare a clean exhibit index in EDGAR with proper hyperlink tagging required by Item 601(b)(105).
• Don’t release marketing materials before effectiveness, because Section 5 prohibits gun jumping.
• Don’t hide major customer concentration in MD&A, because the staff routinely asks for the breakdown.
• Don’t underestimate FINRA review time, because Rule 5110 compensation review can run in parallel but still takes weeks.
• Don’t reuse another company’s risk factors, because the staff will spot the cut-and-paste.
• Don’t forget that Section 11 liability is strict against the issuer and personal against signing officers and directors.

Pros and Cons of Going Public via Form S-1

A Form S-1 IPO has clear trade-offs.

• Pro: Access to the deep U.S. public capital markets, which can fund growth that private rounds cannot match.
• Pro: A liquid trading market for employees and existing investors, which makes equity compensation more valuable.
• Pro: Public currency for acquisitions, because public stock can be used as deal consideration under Form S-4.
• Pro: Higher brand visibility, because press, analysts, and customers all watch public companies.
• Pro: Potential lower cost of capital for established businesses, because public debt and equity often price tighter.
• Con: Heavy ongoing reporting burden under the Exchange Act including 10-Ks, 10-Qs, and 8-Ks.
• Con: Personal liability under Section 11 and Section 12 for officers, directors, and underwriters.
• Con: Significant cost, often \$8 million to \$15 million in legal, audit, printer, and listing fees, plus underwriter discount.
• Con: Short-term earnings pressure from public investors and analysts, which can distort long-term planning.
• Con: Loss of confidentiality, because every material contract, executive pay package, and risk factor goes on EDGAR.

The S-1 Process and Timeline

The S-1 process generally runs four to nine months. The kickoff or “organizational meeting” sets up working groups, drafts a timeline, and assigns responsibility for each section. Counsel and the company prepare the first full draft over six to eight weeks, while auditors finalize PCAOB-compliant financials.

After the first draft, the issuer files the confidential draft registration statement (DRS) on EDGAR. The staff usually responds with a comment letter in about 27 days, per the SEC’s review timing guidance. The issuer files an amendment, and the cycle repeats two or three times. Once comments are cleared, the issuer flips to a public filing, conducts the road show, and asks the staff to declare the registration effective under Rule 461.

Pricing happens after market close on the day of effectiveness. The next morning, the stock opens for trading, and the final prospectus is filed under Rule 424(b). The consequence of missing the 424(b) deadline is a Section 5 violation that can expose the issuer to rescission.

Liability and Key Court Rulings

Section 11 of the Securities Act creates strict liability for the issuer for any material misstatement or omission in the S-1. Officers, directors, signing experts, and underwriters can also be liable, but they have a “due diligence” defense if they performed a reasonable investigation.

Escott v. BarChris Construction Corp., 283 F. Supp. 643 (S.D.N.Y. 1968), is the seminal case on due diligence. The court held that directors, including outside directors, must do more than rubber-stamp management’s drafts. The consequence of failing to investigate is personal liability that insurance often does not fully cover.

In re WorldCom, Inc. Securities Litigation, 346 F. Supp. 2d 628 (S.D.N.Y. 2004), extended the BarChris standard to underwriters in a registered debt offering, holding that they could not rely blindly on audited financials when red flags existed. Wanda Foster, a hypothetical bank capital markets associate, builds her diligence binders specifically to defeat any future BarChris-style claim.

State “Blue Sky” Considerations

Federal registration on Form S-1 does not always preempt state law. Under Section 18 of the Securities Act, securities listed on a national exchange like NYSE or Nasdaq are “covered securities” and are largely exempt from state-by-state Blue Sky review. The consequence of listing on a smaller venue, like the OTCQX, is that you may need to register or obtain exemptions in each state where you sell.

NASAA’s Blue Sky filing guidance lists state-by-state notice filings and fees that issuers and selling shareholders must track. A common misconception is that federal effectiveness equals state effectiveness everywhere, but unlisted issuers must still clear state-level filings to avoid rescission claims.

FAQs

Is Form S-1 the same as an IPO prospectus?

No. The S-1 is the full registration statement filed with the SEC. The prospectus is Part I of that filing and is the document delivered to investors before they buy.

Do I have to use a PCAOB-registered audit firm?

Yes. Section 102 of Sarbanes-Oxley requires PCAOB registration for any auditor issuing reports for SEC filings. Non-registered firm audits are rejected.

Can I keep my Form S-1 confidential at first?

Yes. Emerging growth companies and certain other issuers may submit drafts confidentially under Section 6(e) and SEC staff policy, then file publicly at least 15 days before the road show.

Are two years of audited financials enough?

Yes. Emerging growth companies under the JOBS Act may include only two years of audited income statements. Non-EGCs need three years under Regulation S-X.

Does the SEC approve my offering?

No. The SEC reviews disclosure but does not pass on the merits of the deal. The cover page must include the standard SEC legend confirming this point under Item 501(b)(7).

Can I advertise the IPO on social media before effectiveness?

No. Pre-effective publicity outside narrow safe harbors violates Section 5(c) gun-jumping rules and may force a cooling-off delay.

Is Form S-1 used for secondary offerings?

Yes. S-1 can be used for resale registrations and follow-on offerings when the issuer cannot use the shorter Form S-3 because of float or reporting history.

Do directors face personal liability for an inaccurate S-1?

Yes. Section 11 creates personal liability for every director who signs the S-1, subject to a due diligence defense built on cases like Escott v. BarChris.

Can foreign companies file Form S-1?

No. Foreign private issuers should use Form F-1, which is tailored for non-U.S. registrants and allows IFRS financials.

Does Form S-1 trigger Exchange Act reporting?

Yes. Once effective, the issuer becomes subject to ongoing reporting under Section 15(d) of the Exchange Act and must file 10-Ks, 10-Qs, and 8-Ks.

Is the SEC filing fee refundable if I withdraw?

Yes. Filers can request a credit or refund of unused fees under Rule 457 when they withdraw the registration before effectiveness.

Do I have to file every material contract as an exhibit?

Yes. Item 601(b)(10) requires material contracts as exhibits, although confidential treatment is available for sensitive commercial terms under recent staff guidance.